References
- Manau D, Balasch J, Arroyo V, et al. Circulatory dysfunction in asymptomatic in vitro fertilization patients. Relationship with hyperestrogenemia and activity of endogenous vasodilators. J Clin Endocrinol Metab 1998;83:1489–93
- Junqueira JJ, Bammann RH, Terra RM, et al. Pleural effusion following ovarian hyperstimulation. J Bras Pneumol 2012;38:400–3
- Ferrara N, Davis-Smyth T. The biology of vascular endothelial growth factor. Endocr Rev 1997;18:4–25
- Geva E, Jaffe R. Role of vascular endothelial growth factor in ovarian physiology and pathology. Fertil Steril 2000;74:429–38
- McClure N, Healy DL, Rogers PA, et al. Vascular endothelial growth factor as a capillary permeability factor in ovarian hyperstimulation syndrome. Lancet 1998;344:235–69
- Agrawal R, Chimusoro K, Rayne N, et al. Severe ovarian hyperstimulation syndrome: serum and ascitic fluid concentrations of vascular endothelial growth factor. Curr Opin Obstet Gynecol 1997;9:141–4
- Abramov Y, Barak V, Nisman B, Schehker JG. Vascular endothelial growth factor plasma levels correlate to the clinical picture in severe ovarian hyperstimulation syndrome. Fertil Steril 1997;67:261–5
- Albert A, Garrido N, Mercader A, et al. The role of endothelium in the pathogenesis of ovarian hyperstimulation syndrome. Mol Hum Reprod 2002;8:409–18
- Gomez R, Simon C, Remohi J, Pellicer A. Vascular endothelial growth factor receptor-2 activation induces vascular permeability in hyperstimulated rats, and this effect is prevented by receptor blockade. Endocrinology 2002;143:4339–48
- Alvarez C, Marti-Bonmati L, Novella-Maestre E, et al. Dopamine agonist capergoline reduces hemoconcentration and ascites in hyperstimulated women undergoing assisted reproduction. J Clin Endocrinol Metab 2007;92:2931–7
- Quintana R, Kopcow L, Marconi G, et al. Inhibition of cyclooxygenase-2 (COX-2) by meloxicam decreases the incidence of ovarian hyperstimulation syndrome in a rat model. Fertil Steril 2008;90:1511–16
- Garrison RN, Galloway RH, Heuser LS. Mechanisms of malignant ascites production. J Surg Res 1987;42:126–32
- Reddy P, Liu L, Adhikari D, et al. Oocyte-specific deletion of Pten causes premature activation of the primordial follicle pool. Science 2008;319:611–13
- Jurgens TP, Schaefer C, May A. Treatment of cluster headache in pregnancy and lactation. Cephalalgia 2009;29:391–400
- Tarantola RM, Folk JC, Boldt HC, Mahajan VB. Intravitreal bevacizumab during pregnancy. Retina 2010;30:1405–11
- Wu Z, Huang J, Sadda S. Inadverted use of bevacizumab to treat choroidal neovascularisation during pregnancy: a case report. Ann Acad Med Singapore 2010;39:143–5
- Petrou P, Georgalas I, Giavaras G, et al. Early loss of pregnancy after intravitreal bevacizumab injection. Acta Ophthalmol 2010;88:e136
- Eechoute K, Van der Velt AA, Oosting S, et al. Polymorphisms in endothelial nitric oxide synthase (eNOS) and vascular endothelial growth factor (VEGF) predict sunitinib-induced hypertension. Clin Pharmacol Ther 2012;92:503–10
- Ayar A. Tocolytic effect of parecoxib, a new parenteral cyclo-oxygenase-2-specific inhibitor, on the spontaneous and prostaglandin-induced contractions of rat isolated myometrium. Clin Exp Pharmacol Physiol 2007;34:737–41
- Saylan A, Arioz DT, Koken T, et al. Prevention of ovarian hyperstimulation syndrome in a rat model: efficacy comparison between cabergoline and meloxicam. Acta Obstet Gynecol Scand 2010;89:692–9
- Fatemi HM, Popovic-Todorovic B, Donoso P, et al. Luteal phase oestradiol suppression by letrozole: a pilot study in oocyte donors. Reprod Biomed Online 2008;17:307–11
- Garcia-Velasco JA, Moreno L, Pacheco A, et al. The aromatase inhibitor letrozole increases the concentration of intraovarian androgens and improves in vitro fertilization outcome in low responder patients: a pilot study. Fertil Steril. 2005;84:82–7
- Garcia-Velasco JA, Quea G, Piro M, et al. Letrozle administration during the luteal phase after ovarian stimulation impacts corpus luteum function: a randomized, placebo-controlled trial. Fertil Steril 2009;92:222–5
- Tulandi T, Martin J, Al-Fadhli R, et al. Congenital malformations among 911 newborns conceived after infertility treatment with letrozole or clomiphene citrate. Fertil Steril 2006;85:1761–5
- Forman R, Gill S, Moretti M, et al. Fetal safety of letrozole and clomiphene citrate for ovulation induction. J Obstet Gynaecol Can 2007;29:668–71